Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
279 studies found for:    Thrombocytopenia: Clinical Trials
Show Display Options
Rank Status Study
21 Completed Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
Conditions: Sickle Cell Disease;   Thalassemia;   Anemia;   Granuloma;   Wiskott-Aldrich Syndrome;   Chediak Higashi Syndrome;   Osteopetrosis;   Neutropenia;   Thrombocytopenia;   Hurler Disease;   Niemann-Pick Disease;   Fucosidosis
Intervention: Procedure: Hematopoietic stem cell transplantation
22 Recruiting A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Eltrombopag;   Drug: IVIG infusion
23 Terminated High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study
Conditions: Infant, Premature;   Erythropoietin;   Brain Injury;   Intraventricular Hemorrhage;   Periventricular Leukomalacia;   Neurodevelopmental Outcomes;   Randomized Clinical Trial
Interventions: Drug: Erythropoietin;   Drug: Saline placebo
24 Withdrawn The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
25 Not yet recruiting Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia
Conditions: Adult Immune Thrombocytopenia (ITP);   Dapsone
Interventions: Drug: Dapsone (Disulone®);   Drug: Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";   Drug: Prednisone (Cortancyl®)
26 Recruiting Observational Trial of a Therapeutic Platelet Transfusion Regimen
Conditions: Acute Myeloid Leukemia;   Thrombocytopenia
27 Completed An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Intervention: Drug: Human immunoglobulin intravenous
28 Completed
Has Results
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
29 Completed
Has Results
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
30 Recruiting Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Interventions: Drug: Romiplostim;   Drug: Placebo
31 Enrolling by invitation A Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Cancer
Condition: Gynecologic Cancer
Interventions: Drug: Eltrombopag;   Drug: Placebo
32 Completed
Has Results
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
Condition: Hepatitis C
Interventions: Drug: Eltrombopag;   Drug: Antiviral therapy
33 Terminated Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Thrombocytopenia
Intervention: Biological: romiplostim
34 No longer available Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
35 Completed Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Condition: Antiphospholipid (aPL)-Positive
Intervention: Biological: Study Drug- ALXN1007
36 Terminated
Has Results
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
Conditions: Brain and Central Nervous System Tumors;   Drug/Agent Toxicity by Tissue/Organ;   Lymphoma;   Thrombocytopenia
Interventions: Drug: Rituxan;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Etoposide phosphate;   Drug: Carboplatin;   Drug: Sodium thiosulfate;   Drug: Neupogen;   Drug: Neulasta;   Drug: Cytarabine
37 Completed PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
Conditions: Critical Illness;   Deep Venous Thrombosis
Interventions: Drug: LMWH (Fragmin, dalteparin);   Drug: Unfractionated Heparin
38 Completed SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
Conditions: Leukemia;   Neutropenia;   Thrombocytopenia
Interventions: Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation;   Radiation: radiation therapy
39 Completed A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Methylprednisolone and IVIG;   Drug: Placebo and IVIG
40 Unknown  Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
Conditions: Purpura, Thrombocytopenic, Idiopathic;   Autoimmune Thrombocytopenic Purpura;   Autoimmune Thrombocytopenia;   Chronic Lymphocytic Leukemia;   Non Hodgkin's Lymphoma
Intervention: Drug: Eltrombopag Olamine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years